Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.54 |
| ▸ | NOS1 | P29475 | 4/20 | 0.39 |
| ▸ | NOS2 | P35228 | 4/20 | 0.39 |
| ▸ | NOS3 | P29474 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15658728 | 1.00 | CYP1A2 (0.54) | CYP1A2NOS1NOS2NOS3PPARG | |
| SCHEMBL11099421 | 1.00 | CYP1A2 (0.54) | CYP1A2NOS1NOS2NOS3PPARG | |
| SCHEMBL15658146 | 1.00 | CYP1A2 (0.54) | CYP1A2NOS1NOS2NOS3PPARG | |
| SCHEMBL15658234 | 1.00 | CYP1A2 (0.54) | CYP1A2NOS1NOS2NOS3PPARG | |
| SCHEMBL24668103 | 1.00 | CYP1A2 (0.54) | CYP1A2NOS1NOS2NOS3PPARG | |
| SCHEMBL1301295 | 1.00 | CYP1A2 (0.54) | CYP1A2NOS1NOS2NOS3PPARG | |
| SCHEMBL24667636 | 1.00 | CYP1A2 (0.54) | CYP1A2NOS1NOS2NOS3PPARG | |
| SCHEMBL5998582 | 1.00 | CYP1A2 (0.54) | CYP1A2NOS1NOS2NOS3PPARG | |
| SCHEMBL1930905 | 0.98 | CYP1A2 (0.56) | CYP1A2NOS1NOS2NOS3PPARG | |
| SCHEMBL310717 | 0.92 | CYP1A2 (0.58) | CYP1A2NOS1NOS2NOS3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106635-A1 | HYPOALLERGENIC RECOMBINANT MILK PROTEINS AND COMPOSITIONS COMPRISING THE SAME | Perfect Day, Inc. | 2023-04-06 | — | — | US | disclosed |
| EP-2735581-B1 | COMPOSITION AND POLYMER | ASAHI CHEMICAL IND (JP) | 2021-07-14 | — | — | EP | disclosed |
| US-20210120859-A1 | FORTIFIED PLANT-BASED FORMULATIONS | IVOLUTION ORGANIC WHOLE FOODS INC. (CA) | 2021-04-29 | — | — | US | disclosed |
| US-9738757-B2 | Composition and polymer | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2017-08-22 | — | — | US | disclosed |
| EP-3124561-A1 | ACTIVE ENERGY RAY-CURABLE INKJET INK | Toyo Ink SC Holdings Co., Ltd. (JP) | 2017-02-01 | — | — | EP | disclosed |
| US-20160222168-A1 | Composition and Polymer | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-08-04 | — | — | US | disclosed |
| US-9334371-B2 | Composition and polymer | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-05-10 | — | — | US | disclosed |
| EP-2735581-A1 | COMPOSITION AND POLYMER | Asahi Kasei Chemicals Corporation (JP) | 2014-05-28 | — | — | EP | disclosed |
| US-20140121293-A1 | Composition and Polymer | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20100247467-A1 | ALPHA-SUBSTITUTED CYCLOPENTANECARBONITRILES OR CYCLOHEXANECARBONITRILES AND THEIR USE IN PERFUMERY | FIRMENICH SA (CH) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247467-A1 | ALPHA-SUBSTITUTED CYCLOPENTANECARBONITRILES OR CYCLOHEXANECARBONITRILES AND THEIR USE IN PERFUMERY | PNN, FASN, CYP8B1 | CYP1A2 251/4885NOS1 103/4885NOS2 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.